Pharmaceuticals dominate Roche’s business. But as some of its most successful drugs—such as cancer drugs Avastin and Herceptin—are facing competition, it may look to its Diagnostics unit to make up the difference.
After a year of back and forth, Abbott and Alere are finally nearing a $5.3 billion acquisition. The St. Jude buy rounded out Abbott’s cardiovascular business, but to make room for investment and long-term growth in the space, the company sold off Abbott Medical Optics.
Johnson & Johnson started 2016 by cutting 3,000 jobs, part of a restructuring move to shore up its lagging medical device businesses. The cuts, in its orthopedics, surgery and cardiovascular units, made up 6% of its medical device employees.